AB0957 Limited gender-related differences characterize psoriatic arthritis: data from a monocentric analysis of 306 patients
Authors: N. Luciano, G. Roselli, L. Canziani, G. M. Guidelli, M. Caprioli, M. De Santis, A. Ceribelli, C. Selmi
Journal: Annals of the Rheumatic Diseases (2022)

Background Psoriatic Arthritis (PsA) is characterised by a wide spectrum of clinical phenotypes which are ultimately driving therapeutic choices. The male-to-female ratio of the disease is approximately even but in the last decades some gender differences have been proposed in terms of clinical expression and therapeutic responses. Objectives The aim of this study is to confirm these differences in a real-life cohort of PsA patients. Methods A retrospective data collection has been conducted on a cohort of outpatients with PsA attending our Rheumatology Clinics at Humanitas Research Hospital between January 1 st and December 31 st 2021. All patients were ≥ 18 years old and fulfilled the CASPAR criteria for PsA. For each patient we obtained demographic, laboratory and clinical parameters and registered which domains (peripheral arthritis, axial PsA, skin and/or nail disease, enthesitis, dactylitis) have been involved in the course of the disease. We also collected data regarding any concomitant comorbidities and previous and current therapies. To investigate possible gender specific differences a cross-sectional univariate descriptive analysis was performed. Results Our cohort included 306 patients (169 - 55% - women) with PsA. The median age of disease onset was the same for men and women, also when separately considering skin (median 38 years) and articular presentation (median 48 years). No statistically significant differences were observed when comparing the two groups in terms of clinical phenotypes. In both groups peripheral arthritis was referred by the vast majority of patients (95% of women vs. 93% of men) and similar rates of axial involvement (34% in women vs. 37% in men). Considering current or previous therapies, we found a comparable use of non steroidal anti-inflammatory drugs (43% in both groups), systemic glucocorticoids (9% in men vs 10% in women), conventional synthetic DMARDs and biologic DMARDs and in each group the percentages of patients with a history of bDMARDs targeting TNFalfa, IL12-23 or IL17 failure (women vs men: 11%vs 11%, 9% vs 6% and 4% vs 5% respectively) were essentially the same. A higher proportion of women received apremilast (13% vs. 4% of men, P= 0.003). We also observed differences in terms of comorbidities: in our cohort women were more frequently affected by hypothyroidism (6/137 vs. 23/149 in men, P=0.006), fibromyalgia (2/137 vs 33/149, P&lt;0.001) and neurologic disorders (13/137 vs. 41/149, P=0.001) compared to men. Conclusion Our cohort demonstrated limited gender-related differences in PsA course and therapeutic choices or duration, reporting only higher prevalence of hypothyroidism, fibromyalgia and neurologic disorders in women. Disclosure of Interests Nicoletta Luciano Speakers bureau: Eli-Lilly, Galapagos, Consultant of: Eli-Lilly, Galapagos, Gianmarco Roselli: None declared, Lorenzo Canziani: None declared, Giacomo Maria Guidelli Speakers bureau: Amgen, Eli-Lilly, Galapagos, UCB, Consultant of: Amgen, Eli-Lilly, Galapagos, UCB, Marta Caprioli: None declared, Maria De Santis Grant/research support from: AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Actelion, Boehringer, Italfarmaco, Grunenthal, Roche, Angela Ceribelli Speakers bureau: Amgen, Grant/research support from: Novartis, Lilly, Pfizer, Grunenthal, GSK, Carlo Selmi Speakers bureau: AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Paid instructor for: AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Consultant of: AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Grant/research support from: AbbVie, Amgen, Janssen, Pfizer